Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

321 - 330of 392 News

September 13, 2018

Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals Division

September 05, 2018

Second quarter of 2018

Bayer completes biggest acquisition in its history

September 04, 2018

LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States

September 03, 2018

Brazilian court rules that growers will continue to have access to glyphosate

August 30, 2018

Not intended for U.S. and UK Media

Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimen

August 27, 2018

New data presented at ESC Congress 2018:

Results of COMMANDER HF and MARINER studies with rivaroxaban published

August 27, 2018

Not intended for U.S. and UK Media

Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer

August 24, 2018

Not intended for U.S. and UK Media

Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery disease

August 20, 2018

Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWoche

August 17, 2018

Bayer rejects WirtschaftsWoche report on Dicamba lawsuits

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk